Intensity Therapeutics (INTS) Registration Filing summary

Company overview and business model

• Operates as a late-stage clinical biotechnology company focused on localized cancer reduction and anti-cancer immune activation using direct intratumoral injection of proprietary drug formulations.

• Lead product candidate, INT230-6, combines cisplatin, vinblastine sulfate, and an amphiphilic molecule to enhance tumor penetration and immune response.

• Completed Phase 1/2 and Phase 2 studies; planning Phase 3 and Phase 2/3 studies in 2024 for soft tissue sarcoma and triple negative breast cancer.

• Developed scalable manufacturing and analytical methods, with regulatory alignment on chemistry, manufacturing, and controls for Phase 3 and product registration.

• Incorporated in Delaware, with principal offices in Shelton, CT.

Financial performance and metrics

• As of July 2, 2024, public float was approximately $47.1 million, with 9,234,973 shares held by non-affiliates.

• Last reported sale price of common stock on July 2, 2024, was $4.87 per share.

• Net tangible book value as of March 31, 2024, was $0.70 per share; post-offering, as adjusted net tangible book value would be $1.43 per share, with immediate dilution of $3.44 per share to new investors.

Use of proceeds and capital allocation

• Net proceeds intended for working capital, research and development, business expansion, strategic transactions, and general corporate purposes.

• May also use proceeds for in-licensing, investments, or acquisitions, though no current commitments exist.

• Pending use, proceeds may be invested in investment-grade, interest-bearing securities.